StreetAlpha.app
Home › Stocks › RYTM

Rhythm Pharmaceuticals, Inc. (RYTM)

Healthcare
$112.36
▼ −3.80%
LAST CLOSE · NOV 20

Rhythm Pharmaceuticals develops and sells IMCIVREE, a treatment for rare genetic forms of obesity. It last closed at $112.36 on Nov 20, down 3.80% on the day. The next earnings report for RYTM is expected around Thu, Feb 25, 2027. For the quarter ended Sep 2026, RYTM reported EPS of -$0.61 on revenue of $92.1M, with revenue up 79.6% from a year ago. Over its last 8 reports the stock moved an average of 4.5% the session after earnings. Over the last 12 months RYTM insiders bought $0 of stock on the open market and sold $43.0M, according to SEC Form 4 filings.

AI Auto Pilots
Is RYTM in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold RYTM.

Key Stats

Last 12 months
Results
Revenue
$280.7M
+61.0% vs a year ago
Net income
−$193.8M
−69.0% margin
EPS (diluted)
−$2.91
Free cash flow
−$83.2M
−29.6% margin
Valuation
Market cap
$7.8B
69.3M shares
P/E
–
No P/E while losing money
Price to sales
27.7
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$40.0M
At Sep 30
Debt
$102.7M
At Sep 30
Shareholder equity
$88.0M
Shares outstanding
69.3M
At Nov 2
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $3.2M$3.2MFY2021FY2022: $23.6M$23.6MFY2022FY2023: $77.4M$77.4MFY2023FY2024: $130.1M$130.1MFY2024FY2025: $189.8M$189.8MFY2025

From RYTM's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 3). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · Time not announced
Reported EPS
-$0.61
Quarter ended Sep 2026
Year ago EPS
-$0.82
Same quarter last year
Revenue
$92.1M
+79.6% vs a year ago
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.72Dec '24Mar 2025: -$0.81Mar '25Jun 2025: -$0.75Jun '25Sep 2025: -$0.82Sep '25Dec 2025: -$0.73Dec '25Mar 2026: -$0.83Mar '26Jun 2026: -$0.73Jun '26Sep 2026: -$0.61Sep '26Latest -$0.61
Revenue by quarter
Dec 2024: $41.8MDec '24Mar 2025: $32.7MMar '25Jun 2025: $48.5MJun '25Sep 2025: $51.3MSep '25Dec 2025: $57.3MDec '25Mar 2026: $60.1MMar '26Jun 2026: $71.3MJun '26Sep 2026: $92.1MSep '26Latest $92.1M
How RYTM moved after its last 8 reports
Average move the session after a report ±4.5%
Nov 3, 2026Time not announced−7.5%
Aug 4, 2026Time not announced+2.9%
May 5, 2026Time not announced+7.9%
Feb 26, 2026Time not announced−1.1%
Jan 9, 2026Time not announced+3.6%
Nov 4, 2025Time not announced−7.7%
Aug 5, 2025Time not announced−1.9%
May 7, 2025Time not announced+3.1%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on RYTMStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
Analyst calls from around the web
Last 90 days on RYTM: 0 upgrades, 0 downgrades, 0 initiations · Targets mentioned $160.00
Citizens JmpNew target
Nov 21 $160.00

StreetAlpha's curated list of analyst calls collected from around the web. It may be incomplete or inaccurate, is not a consensus and is not advice.

AI Starter and AI Pro
Full analyst coverage on RYTM
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on RYTM

Technical Analysis

RYTM · as of the Nov 20 close · updated each morning
Uptrend

The stock is 6% above its 20 day and 13% above its 50 day average. It is 13% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 57). The nearest support is the swing low (Aug 12) at $111.42, and the nearest resistance the Pivot at $113.79.

Short trendBullish
Long trendBullish
MomentumStrong
StretchNormal
VolatilityHigh, 5.4%/day
Key levels
$122.2052 week high+8.8%
$115.58Pivot R1+2.9%
$114.75Swing high (Aug 26)+2.1%
$113.79Pivot+1.3%
$112.36Last close
$111.42Swing low (Aug 12)−0.8%
$110.57Pivot S1−1.6%
$105.2220 day average−6.4%
$103.48100 day average−7.9%
$98.0850 day average−12.7%
$97.45200 day average−13.3%
$74.5052 week low−33.7%
Indicators
RSI (14)57.21Middle of its rangeNeutral
MACD5.71Above its signal lineBullish
Stochastic86.6Near the top of its rangeOverbought
ADX (14)30.7Trending up
Williams %R-22.7Oversold below −80, overbought above −20Neutral
CCI (20)62.8Oversold below −100, overbought above 100Neutral
Rate of change+0.1%Change over 10 sessionsBullish
ATR (14)$6.03Typical daily range, 5.4% of price
MA 10Below
MA 20Above
MA 50Above
MA 100Above
MA 200Above
What happened before, for RYTM

What happened before

See how RYTM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow RYTM usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How RYTM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for RYTMHow many large options trades hit RYTM, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

RYTM Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲186 buying vs 115 selling
  • ▲Held by funds +2.4 pts
  • ▲Funds holding +28
  • ▲Superinvestors: 4 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding334306+9.2%
In funds' top 1010100.0%
Held by funds114.0%111.7%+2.4 pts
New / increased56 / 13061 / 104+12.7%
Reduced / sold out85 / 30101 / 41−19.0%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See RYTM institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

RYTM Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$43.0M16 sales · 10 insiders
98% of the selling was under pre-arranged trading plans.
2025-12 sold $372K2026-02 sold $2.2M2026-03 sold $503K2026-05 sold $428K2026-06 sold $3.7M2026-08 sold $23.7M2026-09 sold $5.1M2026-11 sold $6.6MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 18Joseph ShulmanChief Technical OfficerSale plan45,921$119.90$5.5M
Nov 17Christophe JeanDirectorSale plan10,000$109.66$1.1M
Sep 14David P MeekerPresident and CEOSale plan50,000$102.67$5.1M
Aug 31Hunter C SmithCFOSale plan62,774$105.46$6.6M
Aug 13Alastair GarfieldChief Scientific OfficerSale plan7,763$117.57$913K
Aug 13Joseph ShulmanChief Technical OfficerSale plan5,079$119.75$608K
Every insider buy and sale for RYTM over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See RYTM insider trades →

From SEC Form 4 filings by RYTM's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RYTM is in one of them and how their past RYTM trades turned out.

RYTM in the AI portfolios
Loading…

RYTM News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered RYTM in an article yet. Here's the latest on the wider market.

RYTM in the news

About Rhythm Pharmaceuticals

Rhythm Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts, in the United States. It sells IMCIVREE, a treatment that acts on the MC4R pathway in the brain, for patients with certain rare genetic forms of obesity, such as Bardet Biedl syndrome. The company is also developing other MC4R agonist treatments for hypothalamic obesity and other rare conditions. Its customers are patients with these rare diseases, along with the physicians and healthcare providers who treat them.

Headquarters
Boston, MA
Founded
2008